Please provide your email address to receive an email when new articles are posted on . Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that ...
Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy ...
Please provide your email address to receive an email when new articles are posted on . Acoramidis received FDA approval for reduction of CV death and hospitalization in patients with amyloid ...
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) ...
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, ...
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysis This ...
Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced. Offering patients near-complete TTR ...
MINNEAPOLIS, MN—Treatment with acoramidis (Attruby; BridgeBio Pharma) compared with placebo appears to reduce cumulative cardiovascular events by almost half among patients who have transthyretin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results